Tetrahedron 69 (2013) 5580-5587

Contents lists available at SciVerse ScienceDirect

Tetrahedron

journal homepage: www.elsevier.com/locate/tet

Palladium-catalyzed C–H arylation using aryltrifluoroborates in conjunction with a Mn^{III} oxidant under mild conditions

Cydney K. Seigerman, Tiffiny M. Micyus, Sharon R. Neufeldt, Melanie S. Sanford*

University of Michigan, Department of Chemistry, 930 N. University Ave., Ann Arbor, MI 48109, USA

ARTICLE INFO

Article history: Received 22 April 2013 Accepted 24 April 2013 Available online 30 April 2013

ABSTRACT

This paper describes the development of a mild Pd-catalyzed C–H arylation reaction using potassium aryltrifluoroborates in conjunction with $Mn(OAc)_3$ as the oxidant. The scope of this transformation is explored with a variety of different aryltrifluoroborates and arylpyridine substrates. Preliminary mechanistic studies suggest that the reaction proceeds via a high-valent Pd mechanism with C–H activation occurring at or before the rate determining step.

© 2013 Elsevier Ltd. All rights reserved.


1. Introduction

Palladium-catalyzed C–C bond-forming reactions serve as valuable synthetic methods for the formation of aryl–aryl linkages in a wide variety of synthetic contexts.¹ Traditional Pd-catalyzed crosscoupling sequences suffer from the disadvantage that they require two pre-functionalized starting materials. This necessitates the independent preparation of the two coupling partners, which can increase the cost and the number of steps required for the overall target synthesis. In contrast, Pd-catalyzed C–H arylation reactions eliminate the need for at least one prefunctionalization step, and thus can serve as a more expedient strategy for aryl–aryl bond construction.²

Over the past 10 years, numerous Pd-catalyzed C–H arylation reactions have been developed.³ Many different aryl coupling partners have been utilized in these transformations, including diaryliodonium salts,⁴ aryl halides,⁵ aryl C–H bonds,⁶ and organometallic reagents.⁷ Among these, arylboron compounds are particularly attractive for reasons that include their low toxicity, low cost, and high stability.⁸ As such, a number of reports have explored the use of arylboronic acids,⁹ arylboronate esters,¹⁰ and aryltrifluoroborates¹¹ as coupling partners for the C–H arylation of substrates bearing directing groups such as pyridines, anilides, benzoic acids, and oximes. However, the vast majority of these reactions are limited by the requirement for relatively high temperatures (usually \geq 90 °C).¹² Furthermore, additives and promoters such as stoichiometric bases, silver salts, and/or benzoquinone (BQ) are generally required in all of these transformations. These features can limit functional group tolerance and also render the reactions operationally complex. For example, in reactions where insoluble

additives are present, stir rate can be a major factor that impacts reaction yield and scalability.¹³ Finally, the identification of oxidants that are competent and compatible with these transformations can also be a challenge. To date, the vast majority of reported examples of Pd-catalyzed C–H arylation with arylboron reagents involve Cu^{II}- or Ag^I-based oxidants and proceed via Pd^{II/0} catalytic manifolds.

In response to these challenges, we sought to develop an operationally simple and mild method for C–H arylation using readily available arylboron reagents. Our efforts in this area were inspired by our recent development of a related room temperature Pdcatalyzed C–H alkylation reaction using alkyltrifluoroborate salts. This transformation utilizes MnF₃ as a stoichiometric oxidant and proceeds at unprecedentedly low reaction temperatures (Scheme 1).¹⁴ Unlike rare prior examples of Pd-catalyzed C–H alkylation with alkylboron reagents, the MnF₃-mediated transformation is believed to involve C-C bond-forming reductive elimination from a high-valent Pd center. Notably, this alkylation does not require the use of additives like benzoquinone, and it proceeds readily at low temperatures (3-6 h at 25-40 °C) under only mildly acidic conditions. The current paper describes the development, optimization, and scope of a related Pd-catalyzed C-H arylation reaction involving aryltrifluoroborate salts in conjunction



Scheme 1. Pd-catalyzed C–H alkylation with alkyltrifluoroborates in conjunction with ${\rm MnF_3}^{\rm 14}$





Tetrahedror

^{*} Corresponding author. Tel.: +1 734 615 0451; e-mail address: <code>mssanfor@umich.edu</code> (M.S. Sanford).

^{0040-4020/\$ —} see front matter @ 2013 Elsevier Ltd. All rights reserved. http://dx.doi.org/10.1016/j.tet.2013.04.114


with a Mn^{III} oxidant. Preliminary investigations of the mechanism of this transformation are also presented.

2. Results and discussion

2.1. Reaction optimization

We first tested the Pd(OAc)₂-catalyzed C–H arylation of 3methyl-2-phenylpyridine (1) with PhBF₃K under the conditions that had proven optimal for C–H alkylation with CH₃BF₃K [0.10 equiv Pd(OAc)₂, 4 equiv MnF₃, 2 equiv RBF₃K, 8:1:1 TFE/ACOH/ H₂O (TFE=2,2,2-trifluoroethanol), 40 °C, 6 h]. As shown in Eq. 1, this reaction provided the *ortho*-phenylated product **1a** in moderate yield (46%), along with a substantial quantity (14%) of the *ortho*acetoxylated product **1**-OAc. Interestingly, however, the use of a different Mn^{III} oxidant [Mn(OAc)₃] in place of MnF₃ provided a comparable yield of **1a** (34%) without formation of the undesired acetoxylated product **1**-OAc. Consequently, all subsequent optimization studies were conducted with Mn(OAc)₃ as the oxidant. with the reaction conditions (**1j**, **1k**, and **1m**). Interestingly *ortho*substituted 2-methoxyphenyltrifluoroborate provided the C–H arylation product **1e** in 71% yield, compared to a more modest 52% yield using the electronically similar *para*-substituted analogue (**1f**).

A range of substituted 2-arylpyridine derivatives could also be arylated using this methodology. As shown in Table 3, good to excellent yields were obtained for arylpyridine substrates bearing electron-donating substituents at the 2'- or 4'-position (**2a**–**4a**, **10a**). More modest conversions and yields were attained with substrates bearing electron-withdrawing groups on either the arene or the pyridine ring. In some cases where significant starting material remained at the end of the reaction, difficulty in separating phenylated product from starting material led to low isolated yields relative to the calibrated GC yields of the crude reaction mixture (**6a**, **7a**, and **13a**). However, the low isolated yields of **11a** and **12a** are comparable to the GC yields observed for the crude reaction mixtures, and reflect inherently low reactivity/conversion of these substrates under the standard conditions.




Increasing the reaction time to 18 h and the reaction temperature to 50 °C using 2.5 equiv Mn(OAc)₃ and 4 equiv PhBF₃K provided a modest improvement in reaction yield (Table 1, entry 2 vs entry 1). Evaluation of a number of solvent systems under these conditions (entries 3-7) showed that a 1:1 mixture of TFE and AcOH provided the highest yield of 1a at 50 °C (77%, entry 7). Lowering the temperature to 40 or 25 °C resulted in a decrease in vield and conversion (entries 8 and 9). The addition of 1 equiv of NaOAc, an additive that is sometimes used to modulate alkene oxidation reactions using Mn(OAc)₃,¹⁵ had a negligible impact on the yield and conversion with substrate **1** (compare entry 7 with entry 10). Nevertheless, this additive was subsequently found to provide an improvement in yield with some other substrates and aryltrifluoroborates; consequently it was routinely added to the scale-up reactions shown in Tables 2 and 3. The addition of 1 equiv of benzoquinone, which is known to promote the reductive elimination step of Pd^{II/0}-catalyzed C-H arylation reactions, resulted in a significant reduction in both yield and conversion (compare entry 7 with entry 11). Under the optimized reaction conditions, phenylboronic acid, phenylboronic acid pinacol ester, and triphenylboroxine were less effective arylating reagents than PhBF₃K (compare entry 7 with entries 12-14). Finally, as expected, no product was formed in the absence of Pd (entry 15), and only trace quantities of 1a could be detected when Mn^{III} was excluded from the reaction mixture (entry 16).

2.2. Substrate scope

C–H arylation of **1** proceeded smoothly using diverse aryltrifluoroborates (Table 2). Both electron-withdrawing and electrondonating substituents on the ArBF₃K reagent were well tolerated in this transformation. In general, electron-neutral and electronrich aryltrifluoroborates provided the highest yields (between 52 and 80% for mono-arylation products **1a–1f** and **1n**). Potentially sensitive iodide and aldehyde substituents were compatible

Table 1

Optimization of the Pd(OAc)₂-catalyzed C-H phenylation of 1^a



Entry	Solvent	Temp (°C)	Conv ^b (%)	Yield ^b (%)
1 ^c	TFE/AcOH/H ₂ O (8:1:1)	40	73	34
2	TFE/AcOH/H ₂ O (8:1:1)	50	68	56 ^d
3	TFE	50	34	26
4	AcOH	50	76	50 ^d
5	AcOH/H ₂ O (9:1)	50	81	55 ^d
6	TFE/AcOH (9:1)	50	77	58 ^d
7	TFE/AcOH (1:1)	50	84	77
8	TFE/AcOH (1:1)	40	73	70
9	TFE/AcOH (1:1)	25	35	30
10 ^e	TFE/AcOH (1:1)	50	86	77
11 ^f	TFE/AcOH (1:1)	50	56	34
12 ^g	TFE/AcOH (1:1)	50	60	50
13 ^h	TFE/AcOH (1:1)	50	82	60
14 ⁱ	TFE/AcOH (1:1)	50	51	38
15 ^{e,j}	TFE/AcOH (1:1)	50	6	0
16 ^k	TFE/AcOH (1:1)	50	≤ 2	2

^a General conditions: **1** (1 equiv), $Pd(OAc)_2$ (0.10 equiv), $PhBF_3K$ (4 equiv), $Mn(OAc)_3$ (2.5 equiv), solvent (0.067 M in **1**), 18 h.

^b Determined by gas chromatographic analysis of the crude reaction mixture using neopentylbenzene as a standard.

^c Reaction run for 6 h using 4 equiv Mn(OAc)₃ and 2 equiv PhBF₃K.

^d C–H acetoxylation product (\sim 3%) formed.

^e NaOAc (1 equiv) added.

^f Benzoquinone (1 equiv) added.


^g PhB(OH)₂ (4 equiv) was used instead of PhBF₃K.


^h Phenylboronic acid pinacol ester (4 equiv) was used instead of PhBF₃K.

ⁱ 1,3,5-Triphenylboroxine (4 equiv) was used instead of PhBF₃K.

^j Control reaction without Pd.

^k Control reaction without Mn^{III}.





^a Isolated yields.

2.3. Mechanistic studies

A key mechanistic question in this arylation system concerns the role of $Mn(OAc)_3$. Mn^{III} reagents have been previously utilized as oxidants for C–H bond functionalization reactions proposed to involve high-valent Pd-catalysis.^{14,16} Furthermore, our group has recently reported a Pd-catalyzed C–H alkylation reaction employing alkyltrifluoroborates and MnF₃ as a stoichiometric oxidant (Eq. 1, vide supra).¹⁴ Preliminary mechanistic evidence in that system suggests that MnF₃ serves as an oxidant for Pd^{II}. Based on this precedent, we hypothesize that Mn(OAc)₃ likely serves an analogous role in the current arylation system.


To preliminarily probe this possibility, we examined the effect of substituting $Mn(OAc)_3$ with other oxidants under the optimized reaction conditions. A number of oxidants commonly used to promote $Pd^{II/0}$ -catalyzed C–H arylation with organoboron compounds were tested. As shown in Table 4, Cu^{II} and Ag^I-based oxidants provided <10% conversion of 1 and <2% yield of the arylation product 1a (entries 3–5). Low conversion was similarly observed when benzoquinone was used in place of $Mn(OAc)_3$ (entry 6, 17%

conversion, 7% yield). Notably, this reagent may effect C–C bond formation, albeit in low yields, by promoting reductive elimination from Pd^{II} (rather than serving to oxidize Pd^{II}).

In marked contrast, a number of oxidants that are known to be competent for the oxidation of Pd^{II} to Pd^{IV} were capable of promoting this transformation.¹⁷ In particular, the hypervalent iodine reagents PhI(OAc)₂ and PhI(TFA)₂ were highly effective oxidants, providing near quantitative conversion and >80% yield of **1a** (Table 4, entries 11 and 12). These results are consistent with a reaction mechanism involving oxidation of a Pd^{II} intermediate by the bystanding stoichiometric oxidant. Arylation using other known oxidants for Pd^{II}, including *N*-chlorosuccinimide (NCS),¹⁸ *N*-fluoro-2,4,6-trimethylpyridinium triflate (NFTPT),¹⁹ K₂S₂O₈,²⁰ and *t*-BuOOH²⁰ could also be achieved, albeit in modest yield (2–11%). Notably, the use of these oxidants resulted in extensive side reactions of the starting material (32–100% conversion) to form an *ortho*-chlorinated product (using NCS, entry 9, ~22% yield) and/or mixtures of other unidentified side products.

We also conducted experiments to determine the kinetic isotope effect associated with this transformation. The intermolecular






^a Isolated yields.

^bGC yield (from crude reaction mixture) was 24%. ^cGC yield (from crude reaction mixture) was 38%. ^dGC yield (from crude reaction mixture) was 32%. ^eGC yield (from crude reaction mixture) was 20%. ^fGC yield (from crude reaction mixture) was 56%.

Table 4

Evaluation of different oxidants for Pd-Catalyzed C-H phenylation of 1^a



Entry	Oxidant	Conv ^b (%)	Yield ^b (%)
1	Mn(OAc) ₃	84	77
2	MnF ₃	95	57
3	AgCO ₃	≤ 2	≤ 2
4	Ag ₂ O	$\leq 2 \leq 2$	nd
5	$Cu(OAc)_2$	16	nd
6	BQ	17	7
7	$K_2S_2O_8$	100	2
8	t-BuOOH	32	6
9	NCS	64	6 ^c
10	NFTPT	100	11
11	PhI(OAc) ₂	98	83
12	PhI(OTFA) ₂	99	91

 a Conditions: 1 (1 equiv), Pd(OAc)_2 (0.10 equiv), PhBF_3K (4 equiv), oxidant (2.5 equiv), AcOH/TFE (1:1, 0.067 M in 1), 50 $^\circ$ C, 18 h.

^b Determined by gas chromatographic analysis of the crude reaction mixture using neopentylbenzene or hexadecane as an internal standard.

^c C–H chlorination product (\sim 22%) formed.

kinetic isotope effect was established by comparing the initial rates of phenylation of 3-methyl-2-phenylpyridine (1) and 3-methyl-2-phenylpyridine- d_5 (1- d_5) (Eq. 2). The optimized reaction

conditions were employed, although the reactions were run at a lower temperature (36 °C) in order to more conveniently monitor reaction progress. As shown in Fig. 1, the initial reaction rates were significantly different for **1** versus **1**-*d*₅, with k_H/k_D =8.3. This large KIE is markedly different than that observed for a related Pd-catalyzed C–H arylation of arylpyridines using diaryliodonium reagents (k_H/k_D =1).²¹ In the latter system, the rate-limiting step was shown to be oxidation of Pd^{II} to Pd^{IV} by Ph₂I⁺, with C–H activation taking place after the turnover-limiting step (i.e., the resting state of the catalyst is a palladacycle). In contrast, the large KIE observed for C–H arylation using ArBF₃K and Mn(OAc)₃ indicates that the





Fig. 1. Initial rates of C–H arylation with 1 versus 1-d₅.

catalyst resting state under these conditions is not cyclometalated and that C–H bond cleavage occurs before or during the turnoverlimiting step.



3. Conclusion

In summary, this paper describes the development of a mild Pdcatalyzed C–H arylation reaction using aryltrifluoroborates in conjunction with Mn(OAc)₃. This transformation proceeds in good yield for arylpyridine substrates bearing electron-donating substituents at the 2'- and 4'-positions, and moderate yields for substrates bearing electron-withdrawing substituents. A variety of substituted aryl groups can be installed using the corresponding ArBF₃K reagents. Preliminary mechanistic studies suggest that the reaction likely involves high-valent Pd-catalysis and that C–H activation occurs at or before the rate-determining step. Ongoing work aims to elucidate the mechanistic details of this C–H arylation, as well as of the analogous C–H alkylation reactions.

4. Experimental section

4.1. General

All reactions were performed with magnetic stirring in scintillation vials. Flash chromatography was performed on EM Science silica gel 60 (0.040-0.063 mm particle size, 230-400 mesh) and thin layer chromatography was performed on Merck TLC plates pre-coated with silica gel 60 F₂₅₄.

4.2. Materials

Pyridine substrates **7** and **8** were prepared according to literature procedures.^{22,23} Substrates **1–6** and **9** were synthesized via Suzuki coupling of 2-bromo-3-methylpyridine with the corresponding arylboronic acids.²⁴ Pyridine substrates **11–13** were also prepared Suzuki couplings of 2-bromopyridine derivatives with *o*tolylphenylboronic acid.²⁴ Substrate **10** was prepared by Suzuki coupling of 2-methoxyphenylboronic acid with 2-chloropyridine.²⁵ Potassium 2,6-dimethylphenyltrifluoroborate and potassium 3acetylphenyltrifluoroborate were synthesized from the corresponding boronic acids and KHF₂.²⁶ The rest of the aryltrifluoroborates were obtained from commercial sources (Alfa Aesar, Aldrich, and Frontier Scientific). Pd(OAc)₂, MnF₃, and Mn(OAc)₃·2H₂O were obtained from Pressure Chemical, Alfa Aesar, and Strem, respectively. 2,2,2-Trifluoroethanol was obtained from TCI America, and all other solvents were obtained from Fisher Chemical. All commercial substrates, reagents, and solvents were used as received and without further purification.

4.3. Instrumentation

NMR spectra were obtained on a Varian vnmrs 700 (699.76 MHz for ¹H; 175.95 MHz for ¹³C) and a Varian MR400 (376.87 MHz for ¹⁹F). ¹H and ¹³C chemical shifts are reported in parts per million (ppm) relative to TMS, with the residual solvent peak used as an internal reference. Multiplicities are reported as follows: singlet (s), doublet (d), doublet of doublets (dd), doublet of doublets (dd), triplet (t), quartet (q), and multiplet (m). IR spectra were obtained on a Perkin–Elmer Spectrum BX FT-IR spectrometer. Melting points were determined with a Mel-Temp 3.0, a Laboratory Devices Inc, USA instrument, and are uncorrected. HRMS data were obtained on a Micromass AutoSpec Ultima Magnetic Sector mass spectrometer. Gas chromatography was performed on a Shimadzu GC-17A equipped with a Restek Rtx[©]-5 column (15 m, 0.25 mm ID, 0.25 μ m df) and an FID detector. GC yields are reported relative to neopentylbenzene or hexadecane as an internal standard.

4.4. General procedures

4.4.1. General procedure A for isolated products. Substrate, solvent, NaOAc, Pd(OAc)₂, and Mn(OAc)₃·2H₂O were combined in a 20 mL scintillation vial. The vial was sealed with a Teflon-lined cap and heated at 50 °C for 18 h with vigorous stirring. After cooling to room temperature, the reaction mixture was diluted with EtOAc (50 mL) and washed with 10 wt % aqueous Na₂SO₃ (1×15 mL), saturated aqueous NaHCO₃ (2×25 mL), and brine (1×10 mL). The combined aqueous layers were extracted with EtOAc (2×25 mL). The organic layers were then combined, dried over MgSO₄, filtered, and concentrated to afford the crude product, which was purified by column chromatography on silica gel. The characterization data (¹H and ¹³C NMR spectra, IR, and melting points, where appropriate) for previously reported products matched that reported in the literature.

4.4.2. General procedure B for kinetic experiments. Kinetics experiments were run in 4 mL scintillation vials sealed with Teflon-lined caps. Each data point within a kinetics run represents a reaction in an individual vial, with each vial containing a constant concentration of oxidant, catalyst, and substrate. The reported value of initial rate at each time point is the average of three trials, and error is reported as standard deviation. To Pd(OAc)₂ (1.1 mg, 0.0050 mmol, 0.1 equiv) and PhBF₃K (36.8 mg, 0.20 mmol, 4 equiv) in a 4 mL vial was added 0.75 mL of a 0.067 M stock solution of substrate (0.050 mmol, 1 equiv) in AcOH/TFE (1:1), followed by Mn(OAc)₃·H₂O (33.5 mg, 0.125 mmol, 2.5 equiv). The reaction mixtures were heated to 36 °C under vigorous stirring on an aluminum heating-block. The reaction mixtures were quenched after the indicated time by adding 0.5 mL of 10 wt % aqueous Na₂SO₃ and shaking vigorously. The crude reaction mixtures were then diluted with EtOAc (3 mL), and neopentylbenzene was added as an internal standard. The reactions were analyzed by gas chromatography, and the calibrated GC yields of products were determined relative to neopentylbenzene.

4.5. Characterization data for new compounds

4.5.1. 2-(3',5'-Dimethyl-[1,1'-biphenyl]-2-yl)-3-methylpyridine (**1b**). General procedure A was followed using substrate **1** (85 mg, 0.50 mmol, 1.0 equiv), Pd(OAc)₂ (11 mg, 0.050 mmol, 0.10 equiv), NaOAc (41 mg, 0.50 mmol, 1.0 equiv), potassium 3,5-dimethyl phenyltrifluoroborate (424 mg, 2.0 mmol, 4.0 equiv), and Mn(OAc)₃·2H₂O (335 mg, 1.25 mmol, 2.5 equiv) in TFE/AcOH (1:1; 7.5 mL total) at 50 °C for 18 h. Product **1b** was obtained as a clear viscous liquid (110.0 mg, 81% yield, R_{f} =0.12 in 80% hexanes/20% Et₂O). ¹H NMR (700 MHz, C₆D₆): δ 8.53 (d, *J*=4.7 Hz, 1H), 7.52 (dd, *J*=7.2, 1.5 Hz, 1H), 7.43 (dd, *J*=7.4, 1.5 Hz, 1H), 7.27–7.21 (multiple peaks, 2H), 6.93 (s, 2H), 6.78 (d, *J*=7.7 Hz, 1H), 6.65 (dd, *J*=7.7, 4.7 Hz, 1H), 6.62 (s, 1H), 2.02 (s, 6H), 1.67 (s, 3H). $^{13}C{^{1}H}$ NMR (176 MHz, CDCl₃): δ 159.9, 146.5, 141.0, 140.9, 139.6, 137.5, 137.2, 131.8, 129.9, 129.8, 129.7, 128.4, 127.3, 122.0, 121.3, 21.3, 19.0. HRMS EI (*m/z*): [M+H]⁺ calcd for C₂₀H₂₀N: 274.1590; found: 274.1593.

4.5.2. 2-(4'-(tert-Butyl)-[1,1'-biphenyl]-2-yl)-3-methylpyridine (**1c**). General procedure A was followed using substrate **1** (85 mg, 0.50 mmol, 1.0 equiv), Pd(OAc)₂ (11 mg, 0.050 mmol, 0.10 equiv), NaOAc (41 mg, 0.50 mmol, 1.0 equiv), potassium 4-*tert*-butylphenyl-trifluoroborate (480 mg, 2.0 mmol, 4.0 equiv), and Mn(OAc)₃·2H₂O (335 mg, 1.25 mmol, 2.5 equiv) in TFE/ACOH (1:1; 7.5 mL total) at 50 °C for 18 h. Product **1c** was obtained as a clear oil (115.8 mg, 77% yield, R_{f} =0.16 in 80% hexanes/20% Et₂O). ¹H NMR (700 MHz, acetone- d_{6}): δ 8.43 (dd, *J*=4.8, 1.1 Hz, 1H), 7.57–7.44 (multiple peaks, 2H), 7.43 (td, *J*=7.5, 1.8 Hz, 1H), 7.38 (dd, *J*=7.6, 1.1 Hz, 1H), 7.32 (dd, *J*=7.6, 1.1 Hz, 1H), 7.22 (d, *J*=8.6 Hz, 2H), 7.15 (dd, *J*=7.7, 4.8 Hz, 1H), 7.06 (d, *J*=8.6 Hz, 2H), 1.74 (s, 3H), 1.24 (s, 9H). ¹³C{¹H} NMR (176 MHz, CDCl₃): δ 159.8, 149.6, 146.7, 140.6, 139.5, 138.2, 137.5, 131.8, 130.1, 129.8, 128.9, 128.4, 127.3, 124.8, 122.2, 34.5, 31.4, 18.9. HRMS EI (*m*/*z*): [M+H]⁺ calcd for C₂₂H₂₄N: 302.1903; found: 302.1907.

4.5.3. 2-(2'-Methoxy-[1,1'-biphenyl]-2-yl)-3-methylpyridine (1e). General procedure A was followed using substrate 1 (85 mg, 0.50 mmol, 1.0 equiv), Pd(OAc)₂ (11 mg, 0.050 mmol, 0.10 equiv), NaOAc (41 mg, 0.50 mmol, 1.0 equiv), potassium 2-methoxy phenyltrifluoroborate (428 mg, 2.0 mmol, 4.0 equiv), and Mn(OAc)₃·2H₂O (335 mg, 1.25 mmol, 2.5 equiv) in TFE/AcOH (1:1; 7.5 mL total) at 50 °C for 18 h. Product 1e was obtained as a pale yellow liquid (98.2 mg, 71% yield, Rf=0.17 in 60% hexanes/40% Et₂O). ¹H NMR (700 MHz, C₆D₆): δ 8.40 (dd, J=4.8, 1.1 Hz, 1H), 7.53 (dd, J=7.7, 1.1 Hz, 1H), 7.50 (dd, J=7.5, 1.1 Hz, 1H), 7.27-7.20 (multiple peaks, 3H), 6.95 (td, J=8.0, 1.8 Hz, 1H), 6.83 (dd, J=7.7, 1.1 Hz, 1H), 6.67 (t, J=7.5 Hz, 1H), 6.57 (dd, J=7.8, 4.8 Hz, 1H), 6.43 (d, J=8.0 Hz, 1H), 3.12 (s, 3H), 1.87 (s, 3H). ¹³C{¹H} NMR (176 MHz, CDCl₃): § 159.6, 156.1, 146.1, 140.4, 137.6, 137.2, 132.2, 131.6, 131.1, 130.0, 129.7, 128.4, 127.7, 127.3, 121.7, 120.1, 110.4, 55.0, 18.9. HRMS EI (*m*/*z*): [M+H]⁺ calcd for C₁₉H₁₈NO: 276.1383; found: 276.1384.

4.5.4. 2-(3'-Nitro-[1,1'-biphenyl]-2-yl)-3-methylpyridine (1g). General procedure A was followed using substrate 1 (85 mg, 0.50 mmol, 1.0 equiv), Pd(OAc)₂ (11 mg, 0.050 mmol, 0.10 equiv), NaOAc (41 mg, 0.50 mmol, 1.0 equiv), potassium 3-nitrophenyltrifluoroborate (458 mg, 2.0 mmol, 4.0 equiv), and Mn(OAc)₃·2H₂O (335 mg, 1.25 mmol, 2.5 equiv) in TFE/AcOH (1:1; 7.5 mL total) at 50 °C for 18 h. Product 1g was obtained as a pale yellow solid (79.3 mg, 55% yield, *R*_f=0.13 in 60% hexanes/40% Et₂O, mp=75.7-76.5 °C). ¹H NMR $(700 \text{ MHz}, \text{ acetone-}d_6)$: δ 8.43 (dd, *J*=4.8, 1.1 Hz, 1H), 8.06 (ddd, *J*=8.2, 2.4, 1.0 Hz, 1H), 7.97 (t, J=2.0 Hz, 1H), 7.62–7.55 (multiple peaks. 4H). 7.51 (t, J=8.0 Hz, 1H), 7.47 (d, J=7.7 Hz, 1H), 7.44 (d, J=7.4 Hz, 1H), 7.18 (dd, J=7.7, 4.8 Hz, 1H), 1.85 (s, 3H). ¹³C{¹H} NMR (176 MHz, CDCl₃): δ 158.6, 148.0, 147.0, 142.8, 139.7, 138.3, 138.0, 135.4, 131.6, 130.2, 129.7, 128.9, 128.8, 128.7, 124.1, 122.7, 121.7, 19.0. IR (thin film): 1527.2, 1349.5 cm⁻¹. HRMS EI (m/z): $[M+H]^+$ calcd for C₁₈H₁₅N₂O₂: 291.1128; found: 291.1133.

4.5.5. 2-(4'-Cyano-[1,1'-biphenyl]-2-yl)-3-methylpyridine (**1h**). General procedure A was followed using substrate **1** (85 mg, 0.50 mmol, 1.0 equiv), Pd(OAc)₂ (11 mg, 0.050 mmol, 0.10 equiv), NaOAc (41 mg, 0.50 mmol, 1.0 equiv), potassium 4-cyanophenyltrifluoroborate (418 mg, 2.0 mmol, 4.0 equiv), and Mn(OAc)₃·2H₂O (335 mg, 1.25 mmol, 2.5 equiv) in TFE/AcOH (1:1; 7.5 mL total) at 50 °C for 18 h. Product **1h** was obtained as a pale yellow solid (65.2 mg, 48% yield, R_{f} =0.10 in 60% hexanes/40% Et₂O, mp=153.6-157.4 °C). ¹H NMR (700 MHz, CDCl₃): δ 8.46 (d, *J*=4.7 Hz, 1H), 7.53-7.49 (multiple peaks, 2H), 7.47-7.41 (multiple peaks, 4H), 7.36 (d, *J*=7.7 Hz, 1H), 7.22 (d,

J=7.9 Hz, 2H), 7.13 (dd, *J*=7.6, 4.7 Hz, 1H), 1.80 (s, 3H). ¹³C{¹H} NMR (176 MHz, CDCl₃): δ 232.3, 158.7, 147.0, 146.1, 139.6, 139.0, 138.0, 131.8, 131.6, 130.3, 130.0, 129.7, 128.8, 122.7, 119.0, 110.6, 19.0. IR (thin film): 2226.5 cm⁻¹. HRMS EI (*m*/*z*): [M+H]⁺ calcd for C₁₉H₁₅N₂: 271.1235; found: 271.1234.

4.5.6. 2'-(3-*Methylpyridin*-2-*yl*)-[1,1'-*biphenyl*]-4-*carbaldehyde* (**1***j*). General procedure A was followed using substrate **1** (42 mg, 0.25 mmol, 1.0 equiv), Pd(OAc)₂ (5.6 mg, 0.025 mmol, 0.10 equiv), NaOAc (21 mg, 0.25 mmol, 1.0 equiv), potassium 4-formylphenyl trifluoroborate (212 mg, 1.0 mmol, 4.0 equiv), and Mn(OAc)₃·2H₂O (168 mg, 0.625 mmol, 2.5 equiv) in TFE/ACOH (1:1; 3.8 mL total) at 50 °C for 18 h. Product **1***j* was obtained as a white solid (25.6 mg, 37% yield, R_{f} =0.07 in 60% hexanes/40% Et₂O, mp=126.1–127.8 °C). ¹H NMR (700 MHz, CDCl₃): δ 9.94 (s, 1H), 8.49 (d, *J*=4.8 Hz, 1H), 7.68 (d, *J*=8.4 Hz, 2H), 7.53–7.47 (multiple peaks, 3H), 7.44 (m, 1H), 7.33 (d, *J*=7.6 Hz, 1H), 7.29 (d, *J*=8.2 Hz, 2H), 7.12 (dd, *J*=7.6, 4.8 Hz, 1H), 1.80 (s, 3H). ¹³C{¹H} NMR (176 MHz, CDCl₃): δ 192.2, 158.9, 147.7, 146.9, 139.7, 139.5, 137.9, 134.7, 131.7, 130.3, 130.0, 129.8, 129.4, 128.7, 128.6, 122.6, 19.0. IR (thin film): 1701.6, 1604.9 cm⁻¹. HRMS EI (*m/z*): [M+H]⁺ calcd for C₁₉H₁₆NO: 274.1226; found: 274.1225.

4.5.7. 2-(3'-Fluoro-[1,1'-biphenyl]-2-yl)-3-methylpyridine (11). General procedure A was followed using substrate 1 (94 mg, 0.50 mmol, 1.0 equiv), Pd(OAc)₂ (11 mg, 0.050 mmol, 0.10 equiv), NaOAc (41 mg, 0.50 mmol, 1.0 equiv), potassium 3-fluorophenyltrifluoroborate (404 mg, 2.0 mmol, 4.0 equiv), and Mn(OAc)₃·2H₂O (335 mg, 1.25 mmol, 2.5 equiv) in TFE/AcOH (1:1; 7.5 mL total) at 50 °C for 18 h. Product 11 was obtained as a greasy yellow solid (75.3 mg, 57% yield, $R_{f}=0.13$ in 80% hexanes/20% Et₂O). ¹H NMR (700 MHz, CDCl₃): δ 8.49 (d, *J*=4.6 Hz, 1H), 7.50–7.43 (multiple peaks, 3H), 7.40 (d, *J*=7.0 Hz, 1H), 7.34 (d, J=7.7 Hz, 1H), 7.41-7.09 (multiple peaks, 2H), 6.90-6.82 (multiple peaks, 3H), 1.80 (s, 3H). ¹³C{¹H} NMR (176 MHz, CDCl₃): δ 162.4 (d, ${}^{1}J_{C-F}$ =245.3 Hz), 159.2, 146.8, 143.5 (d, ${}^{3}J_{C-F}$ =7.5 Hz), 139.6, 139.5 (d, ⁴*J*_{C-F}=2.0 Hz), 137.7, 131.7, 130.1, 129.7, 129.3 (d, ³*J*_{C-F}=8.6 Hz), 128.6, 128.1, 125.2 (d, ${}^{4}J_{C-F}=2.9$ Hz), 122.4, 116.2 (d, ${}^{2}J_{C-F}=21.4$ Hz), 113.7 (d, ${}^{2}J_{C-F}=21.0$ Hz), 19.0 ${}^{19}F{}^{1}H$ NMR (377 MHz, CDCl₃): δ –113.7 (m, 1F). HRMS EI (*m*/*z*): [M+H]⁺ calcd for C₁₈H₁₅FN: 264.1183; found: 264.1186.

4.5.8. 2-(4'-lodo-[1,1'-biphenyl]-2-yl)-3-methylpyridine (**1m**). General procedure A was followed using substrate **1** (85 mg, 0.50 mmol, 1.0 equiv), Pd(OAc)₂ (11 mg, 0.050 mmol, 0.10 equiv), NaOAc (41 mg, 0.50 mmol, 1.0 equiv), potassium 4-iodophenyltrifluoroborate (608 mg, 2.0 mmol, 4.0 equiv), and Mn(OAc)₃·2H₂O (335 mg, 1.25 mmol, 2.5 equiv) in TFE/AcOH (1:1; 7.5 mL total) at 50 °C for 18 h. Product **1m** was obtained as a white solid (87.5 mg, 41% yield, R_f =0.11 in 80% hexanes/20% Et₂O, mp=108.6–113.9 °C). ¹H NMR (700 MHz, C₆D₆): δ 8.55 (d, *J*=4.6 Hz, 1H), 7.52 (m, 1H), 7.36 (d, *J*=8.4 Hz, 2H), 7.30–7.27 (multiple peaks, 3H), 6.87 (d, *J*=8.4 Hz, 2H), 6.82 (d, *J*=7.8 Hz, 1H), 6.71 (dd, *J*=7.7, 4.6 Hz, 1H), 1.65 (s, 3H). ¹³C{¹H} NMR (176 MHz, CDCl₃): δ 159.2, 146.8, 140.8, 139.6, 139.5, 137.8, 137.1, 131.7, 131.3, 130.1, 129.6, 128.6, 128.0, 122.4, 92.8, 19.0. HRMS EI (*m/z*): [M+H]⁺ calcd for C₁₈H₁₅IN: 372.0244; found: 372.0245.

4.5.9. 2-(3'-Methoxy-[1,1'-biphenyl]-2-yl)-3-methylpyridine (**1n**). General procedure A was followed using substrate **1** (85 mg, 0.50 mmol, 1.0 equiv), Pd(OAc)₂ (11 mg, 0.050 mmol, 0.10 equiv), NaOAc (41 mg, 0.50 mmol, 1.0 equiv), potassium 3-methoxyphenyl trifluoroborate (428 mg, 2.0 mmol, 4.0 equiv), and Mn(OAc)₃·2H₂O (335 mg, 1.25 mmol, 2.5 equiv) in TFE/ACOH (1:1; 7.5 mL total) at 50 °C for 18 h. Product **1n** was obtained as a pale yellow liquid (102.0 mg, 74% yield, R_{f} =0.18 in 60% hexanes/40% Et₂O). ¹H NMR (700 MHz, C₆D₆): δ 8.51 (d, *J*=4.7 Hz, 1H), 7.59–7.43 (multiple peaks, 3H), 7.40 (d, *J*=7.4 Hz, 1H), 7.31 (d, *J*=7.8 Hz, 1H), 7.13–7.09 (multiple peaks, 2H), 6.80 (d, *J*=7.6 Hz, 1H), 6.72 (dd, *J*=8.2, 2.5 Hz, 1H), 6.59 (s, 1H), 3.55 (s, 3H), 1.77 (s, 3H). ¹³C{¹H} NMR (176 MHz, CDCl₃): δ 159.8, 159.0, 146.6, 142.6, 140.6, 139.6, 137.6, 132.0, 130.0, 129.7, 129.0, 128.5, 127.7, 122.3, 121.7, 114.4, 113.4, 55.1, 19.0. HRMS EI (*m*/*z*): [M+H]⁺ calcd for C₁₉H₁₈NO: 276.1388; found: 276.1389.

4.5.10. 2-(5-(tert-Butyl)-[1,1'-biphenyl]-2-yl)-3-methylpyridine (2a). General procedure A was followed using substrate 2 (113 mg. 0.50 mmol, 1.0 equiv), Pd(OAc)₂ (11 mg, 0.050 mmol, 0.10 equiv). NaOAc (41 mg, 0.50 mmol, 1.0 equiv), potassium phenyltrifluoroborate (368 mg, 2.0 mmol, 4.0 equiv), and Mn(OAc)₃·2H₂O (335 mg, 1.25 mmol, 2.5 equiv) in TFE/AcOH (1:1; 7.5 mL total) at 50 °C for 18 h. Product 2a was obtained as a pale yellow solid (130.0 mg, 86% yield, R_f=0.15 in 80% hexanes/20% Et₂O, mp=129.6–133.0 °C). ¹H NMR (700 MHz, C_6D_6): δ 8.53 (d, J=4.8 Hz, 1H), 7.59 (d, J=2.0 Hz, 1H), 7.53 (d, J=8.0 Hz, 1H), 7.37-7.32 (multiple peaks, 3H), 7.03–6.99 (multiple peaks, 2H), 6.95 (dd, *I*=7.1, 1.0 Hz, 1H), 6.78 (dd, J=7.7, 1.0 Hz, 1H), 6.64 (dd, J=7.7, 4.8 Hz, 1H), 1.67 (s, 3H), 1.26 (s, 9H). ¹³C{¹H} NMR (176 MHz, CDCl₃): δ 159.7, 151.3, 146.7, 141.9, 140.3, 137.5, 136.7, 131.8, 129.7, 129.4, 127.9, 126.8, 126.5, 124.6, 122.0, 34.8, 31.5, 19.1. HRMS EI (*m*/*z*): [M+H]⁺ calcd for C₂₂H₂₄N: 302.1909; found: 302.1903.

4.5.11. 2-(5-Methoxy-[1,1'-biphenyl]-2-yl)-3-methylpyridine (**4a**). General procedure A was followed using substrate **4** (100 mg, 0.50 mmol, 1.0 equiv), Pd(OAc)₂ (11 mg, 0.050 mmol, 0.10 equiv), NaOAc (41 mg, 0.50 mmol, 1.0 equiv), potassium phenyl-trifluoroborate (368 mg, 2.0 mmol, 4.0 equiv), and Mn(OAc)₃· 2H₂O (335 mg, 1.25 mmol, 2.5 equiv) in TFE/ACOH (1:1; 7.5 mL total) at 50 °C for 18 h. Product **4a** was obtained as a clear oil (102.1 mg, 71% yield, R_{f} =0.14 in 60% hexanes/40% Et₂O). ¹H NMR (700 MHz, C₆D₆): δ 8.53 (d, J=4.7 Hz, 1H), 7.44 (d, J=8.4 Hz, 1H), 7.28 (multiple peaks, 2H), 7.06 (d, J=2.7, 1H), 6.99–6.90 (multiple peaks, 3H), 6.84 (dd, J=8.3, 2.7 Hz, 1H), 6.78 (d, J=7.5 Hz, 1H), 6.64 (dd, J=7.5, 4.8 Hz, 1H), 3.34 (s, 3H), 1.68 (s, 3H). ¹³C{¹H} NMR (176 MHz, CDCl₃): δ 159.6, 159.4, 146.7, 142.1, 141.2, 137.5, 132.3, 132.0, 131.3, 129.3, 127.9, 126.9, 122.0, 115.1, 113.1, 55.5, 19.0. HRMS EI (*m*/*z*): [M+H]⁺ calcd for C₁₉H₁₈NO: 276.1383; found: 276.1385.

4.5.12. 2-(5-Fluoro-[1,1'-biphenyl]-2-yl)-3-methylpyridine (5a). General procedure A was followed using substrate 5 (94 mg, 0.50 mmol, 1.0 equiv), Pd(OAc)₂ (11 mg, 0.050 mmol, 0.10 equiv), NaOAc (41 mg, 0.50 mmol, 1.0 equiv), potassium phenyltrifluoroborate (368 mg, 2.0 mmol, 4.0 equiv), and Mn(OAc)₃·2H₂O (335 mg, 1.25 mmol, 2.5 equiv) in TFE/AcOH (1:1; 7.5 mL total) at 50 °C for 18 h. Product 5a was obtained as a white powder (60.5 mg, 46% yield, R_f =0.13 in 80% hexanes/20% Et₂O, mp=97.2-99.4 °C). ¹H NMR (700 MHz, C_6D_6): δ 8.47 (d, *I*=4.8 Hz, 1H), 7.25 (dd, *I*=8.2, 6.0 Hz, 1H), 7.08 (d, J=7.5 Hz, 2H), 7.07 (dd, J=9.9, 2.3 Hz, 1H), 6.94–6.87 (multiple peaks, 3H), 6.85 (td, J=8.4, 2.6 Hz, 1H), 6.74 (d, *J*=7.6 Hz, 1H), 6.62 (dd, *J*=7.6, 4.8 Hz, 1H), 1.54 (s, 3H). ¹³C{¹H} NMR (176 MHz, CDCl₃): δ 162.7 (d, ¹*J*_{C-F}=246.8 Hz), 158.7, 146.8, 142.9 (d, ³*J*_{C-F}=7.5 Hz), 140.1 (d, ⁴*J*_{C-F}=2.1 Hz), 137.7, 135.7 (d, ⁴*J*_{C-F}=3.2 Hz), 131.9, 131.8 (d, ${}^{3}J_{C-F}$ =8.5 Hz), 129.2, 128.1, 127.3, 122.4, 116.5 (d, $^{2}J_{C-F}$ =21.8 Hz), 114.4 (d, $^{2}J_{C-F}$ =21.5 Hz), 18.9. $^{19}F{^{1}H}$ NMR $(377 \text{ MHz}, C_6D_6): \delta - 114.3 \text{ (m, 1F)}. \text{ HRMS EI } (m/z): [M+H]^+ \text{ calcd for}$ C₁₈H₁₅FN: 264.1183; found: 264.1189.

4.5.13. 6-(3-*Methylpyridin-2-yl*)-[1,1'-*biphenyl*]-3-*carbaldehyde* (*6a*). General procedure A was followed using substrate **6** (99 mg, 0.50 mmol, 1.0 equiv), Pd(OAc)₂ (11 mg, 0.050 mmol, 0.10 equiv), NaOAc (41 mg, 0.50 mmol, 1.0 equiv), potassium phenyl-trifluoroborate (368 mg, 2.0 mmol, 4.0 equiv), and Mn(OAc)₃·2H₂O (335 mg, 1.25 mmol, 2.5 equiv) in TFE/ACOH (1:1; 7.5 mL total) at 50 °C for 18 h. Product **6a** was obtained as a white solid (13.5 mg, 10% yield, *R*_{*f*}=0.09 in 80% hexanes/20% Et₂O, mp=105.4–106.4 °C). ¹H NMR (700 MHz, CDCl₃): δ 10.13 (s, 1H), 8.52 (d, *J*=4.5 Hz, 1H), 7.99 (s, 1H), 7.96 (d, *J*=7.8 Hz, 1H), 7.59 (d, *J*=7.8 Hz, 1H), 7.33 (d, *J*=7.8 Hz, 1H), 7.23–7.17 (multiple peaks, 3H), 7.16–7.12 (multiple peaks, 3H), 1.76 (s, 3H). $^{13}C{}^{1}H$ NMR (176 MHz, CDCl₃): δ 192.2, 158.3, 146.9, 145.5, 141.9, 139.8, 137.9, 136.4, 131.6, 131.4, 131.1, 129.3, 128.6, 128.2, 127.5, 122.8, 18.8. IR (thin film): 1697.8 cm⁻¹. HRMS EI (*m*/*z*): [M+H]⁺ calcd for C₁₉H₁₆NO: 274.1226; found: 274.1232.

4.5.14. 2-(5-Chloro-[1,1'-biphenyl]-2-yl)-3-methylpyridine(**7a**). General procedure A was followed using substrate **7** (102 mg, 0.50 mmol, 1.0 equiv), Pd(OAc)₂ (11 mg, 0.50 mmol, 0.10 equiv), NaOAc (41 mg, 0.50 mmol, 1.0 equiv), potassium phenyl-trifluoroborate (368 mg, 2.0 mmol, 4.0 equiv), and Mn(OAc)₃· 2H₂O (335 mg, 1.25 mmol, 2.5 equiv) in TFE/ACOH (1:1; 7.5 mL total) at 50 °C for 18 h. Product **7a** was obtained as a clear viscous oil (19.5 mg, 14% yield, R_f =0.08 in 88% hexanes/12% Et₂O). ¹H NMR (700 MHz, CDCl₃): δ 8.49 (d, *J*=4.5, 1H), 7.46 (d, *J*=2.1 Hz, 1H), 7.42 (dd, *J*=8.2, 2.1 Hz, 1 H), 7.35 (d, *J*=8.1 Hz, 1H), 7.30 (d, *J*=7.3, 1H), 7.20–7.14 (multiple peaks, 3H), 7.13–7.07 (multiple peaks, 3H), 1.74 (s, 3H). ¹³C {¹H} NMR (176 MHz, CDCl₃): δ 158.5, 146.9, 142.5, 139.9, 138.1, 137.7, 134.2, 131.8, 131.5, 129.7, 129.2, 128.1, 127.6, 127.3, 122.5, 18.9. HRMS EI (*m*/*z*): [M+H]⁺ calcd for C₁₈H₁₅CIN: 280.0888; found: 280.0893.

4.5.15. 2-(4-Bromo-[1,1'-biphenyl]-2-yl)-3-methylpyridine(**8a**). General procedure A was followed using substrate **8** (124 mg, 0.50 mmol, 1.0 equiv), Pd(OAc)₂ (11 mg, 0.050 mmol, 0.10 equiv), NaOAc (41 mg, 0.50 mmol, 1.0 equiv), potassium phenyltrifluoroborate (368 mg, 2.0 mmol, 4.0 equiv), and Mn(OAc)₃·2H₂O (335 mg, 1.25 mmol, 2.5 equiv) in TFE/AcOH (1:1; 7.5 mL total) at 50 °C for 18 h. Product **8a** was obtained as a white solid (74.3 mg, 46% yield, R_f =0.29 in 80% hexanes/20% Et₂O, mp=84.7–88.2 °C). ¹H NMR (700 MHz, C₆D₆): δ 8.42 (d, *J*=4.6 Hz, 1H), 7.65 (d, *J*=2.0 Hz, 1H), 7.32 (dd, *J*=8.3, 2.0 Hz, 1H), 7.10 (d, *J*=7.1 Hz, 2H), 6.97–6.88 (multiple peaks, 4H), 6.69 (d, *J*=7.6, 1H), 6.60 (dd, *J*=7.8, 4.7 Hz, 1H), 1.49 (s, 3H). ¹³C{¹H} NMR (176 MHz, CDCl₃): δ 157.9, 146.7, 141.2, 139.9, 139.6, 137.7, 132.8, 131.6, 131.4, 131.2, 129.0, 127.9, 127.0, 122.5, 121.4, 18.7. HRMS EI (*m/z*): [M+H]⁺ calcd for C₁₈H₁₅BrN: 324.0388; found: 324.0384.

4.5.16. 2-(4-Methoxy-[1,1'-biphenyl]-2-yl)-3-methylpyridine (**9a**). General procedure A was followed using substrate **9** (100 mg, 0.50 mmol, 1.0 equiv), Pd(OAc)₂ (11 mg, 0.050 mmol, 0.10 equiv), NaOAc (41 mg, 0.50 mmol, 1.0 equiv), potassium phenyl-trifluoroborate (368 mg, 2.0 mmol, 4.0 equiv), and Mn(OAc)₃· 2H₂O (335 mg, 1.25 mmol, 2.5 equiv) in TFE/ACOH (1:1; 7.5 mL total) at 50 °C for 18 h. Product **9a** was obtained as a pale yellow oil (51.9 mg, 38% yield, R_{f} =0.18 in 60% hexanes/40% Et₂O). ¹H NMR (700 MHz, CDCl₃): δ 8.51 (d, *J*=4.9 Hz, 1H), 7.38 (d, *J*=8.6 Hz, 1H), 7.29 (d, *J*=7.7 Hz, 1H), 7.15–7.12 (multiple peaks, 3H), 7.10 (dd, *J*=7.7, 4.9 Hz, 1H), 7.09–7.06 (multiple peaks, 2H), 7.03 (dd, *J*=8.6, 2.7 Hz, 1H), 6.94 (d, *J*=2.7 Hz, 1H), 3.37 (s, 3H), 1.75 (s, 3H). ¹³C{¹H} NMR (176 MHz, CDCl₃): δ 159.5, 159.0, 146.7, 140.9, 140.6, 137.7, 133.6, 131.7, 131.1, 129.3127.9, 126.3, 122.3, 114.8, 114.7, 55.6, 18.9. HRMS EI (*m*/*z*): [M+H]⁺ calcd for C₁₉H₁₈NO: 276.1383; found: 276.1384.

4.5.17. 2-(3-*Methyl-[1,1'-biphenyl]-2-yl)-5-(trifluoromethyl)pyridine* (**13a**). General procedure A was followed using substrate **14** (137 mg, 0.50 mmol, 1.0 equiv), Pd(OAc)₂ (11 mg, 0.050 mmol, 0.10 equiv), NaOAc (41 mg, 0.50 mmol, 1.0 equiv), potassium phenyltrifluoroborate (368 mg, 2.0 mmol, 4.0 equiv), and Mn(OAc)₃·2H₂O (335 mg, 1.25 mmol, 2.5 equiv) in TFE/AcOH (1:1; 7.5 mL total) at 50 °C for 18 h. Product **13a** was obtained as pale yellow needles (45.5 mg, 29% yield, R_{f} =0.29 in 94% hexanes/6% Et₂O, mp=101.3–104.3 °C). ¹H NMR (700 MHz, acetone- d_6): δ 8.94 (s, 1H), 7.91 (dd, *J*=8.3, 2.2 Hz, 1H), 7.42 (t, *J*=7.6 Hz, 1H), 7.35 (d, *J*=7.7 Hz, 1H), 7.28 (d, *J*=7.7 Hz, 1H), 7.19–7.12 (multiple peaks, 4H), 7.07–7.03 (multiple peaks, 2H), 2.13 (s, 3H). ¹³C{¹H} NMR (176 MHz, CDCl₃): δ 163.6, 145.9 (q, ³*J*_{C-F}=4.2 Hz), 141.4, 141.2, 138.2, 136.7,

132.9 (q, $^3\!J_{C-F}{=}3.4$ Hz), 129.8, 129.7, 128.8, 128.0, 127.9, 126.8, 125.6, 124.3 (q, $^2\!J_{C-F}{=}34$ Hz), 123.8 (q, $^1\!J_{C-F}{=}272.8$ Hz), 20.6. $^{19}F\{^1H\}$ NMR (377 MHz, CDCl₃): δ –62.8. (s, 3F). HRMS EI (*m*/*z*): [M+H]⁺ calcd for C₁₉H₁₅F₃N: 314.1151; found: 314.1153.

Acknowledgements

This work was supported by the NIH NIGMS (GM073836).

References and notes

- 1. For reviews on Pd-catalvzed C-C cross-coupling reactions, see: (a) Corbet, J. P.; Mignani, G. Chem. Rev. 2006, 106, 2651; (b) Liu, C.; Zhang, H.; Shi, W.; Lei, A. Chem. Rev. 2011, 111, 1780.
- 2 (a) Hassan, J.; Sevignon, M.; Gozzi, C.; Schulz, E.; Lemaire, M. Chem. Rev. 2002, 102, 1359; (b) Nicolaou, K. C.; Bulger, P. G.; Sarlah, D. Angew. Chem., Int. Ed. 2005, 44 4442
- 3. For recent reviews, see: (a) Alberico, D.; Scott, M. E.; Lautens, M. Chem. Rev. 2007. 107. 174: (b) McGlacken, G. P.: Bateman, L. M. Chem. Soc. Rev. 2009. 38. 2447
- Deprez, N. R.; Sanford, M. S. Inorg. Chem. 2007, 46, 1924.
 Daugulis, O. Top. Curr. Chem. 2010, 292, 57.
- For recent reviews, see: (a) Yeung, C. S.; Dong, V. M. Chem. Rev. 2011, 111, 1215; 6. (b) You, S.; Xia, J. Top. Curr. Chem. 2010, 292, 165.
- Ackermann, L.; Vicente, R.; Kapdi, A. R. Angew. Chem., Int. Ed. 2009, 48, 9792.
- (a) Molander, G. A.; Ellis, N. Acc. Chem. Res. 2007, 40, 275; (b) Darses, S.; Genet, 8 J.-P. Chem. Rev. 2008, 108, 288; (c) Molander, G. A.; Sandrock, D. L. Curr. Opin. Drug Discov. Dev. 2009, 12, 811.
- (a) Chen, X.; Goodhue, C. E.; Yu, J.-Q. J. Am. Chem. Soc. 2006, 128, 12634; (b) Shi, Z.; Li, B.; Wan, X.; Cheng, J.; Fang, Z.; Cao, B.; Qin, C.; Wang, Y. Angew. Chem., Int. Ed. 2007, 46, 5554; (c) Wang, D.-H.; Wasa, M.; Giri, R.; Yu, J.-Q. J. Am. Chem. Soc. 2008, 130, 7190; (d) Chu, J.-H.; Chen, C.-C.; Wu, M.-J. Organometallics 2008, 27, 5173; (e) Yang, S.-D.; Sun, C.-L.; Fang, Z.; Li, B.-J.; Li, Y.-Z.; Shi, Z.-J. Angew. Chem., Int. Ed. 2008, 47, 1473; (f) Kirchberg, S.; Fröhlich, R.; Studer, A. Angew. Chem., Int. Ed. 2009, 48, 4235; (g) Gu, S.; Chen, C.; Chen, W. J. Org. Chem. 2009, 74, 7203; (h) Sun, C.-L.; Liu, N.; Li, B.-J.; Yu, D.-G.; Wang, Y.; Shi, Z.-J. Org. Lett. 2010, 12, 184; (i) Engle, K. M.; Thuy-Boun, P. S.; Dang, M.; Yu, J.-Q. J. Am. Chem. Soc. 2011, 133, 18183; (j) Kim, Y. W.; Niphakis, M. J.; Georg, G. I. J. Org. Chem. 2012, 77, 9496; (k) Koley, M.; Dastbaravardeh, N.; Schnürch, M.; Mihovilovic, M. D. ChemCatChem 2012, 4, 1345; (1) Chu, J.-H.; Wu, C.-C.; Chang, D.-H.; Lee, Y.-M.; Wu, M.-J. Organometallics 2012, 32,

272; (m) Salvanna, N.; Reddy, G. C.; Das, B. Tetrahedron 2013, 69, 2220; (n) Gao, D.-W.; Shi, Y.-C.; Gu, O.; Zhao, Z.-L.; You, S.-L. J. Am. Chem. Soc. 2013, 135, 86.

- 10. (a) Giri, R.; Maugel, N.; Li, J.-J.; Wang, D.-H.; Breazzano, S. P.; Saunders, L. B.; Yu, I.-Q. J. Am. Chem. Soc. 2007, 129, 3510; (b) Romero-Revilla, J. A.; García-Rubia, A.; Arrayás, R.; Fernández-Ibáñez, M. Á.; Carretero, J. C. J. Org. Chem. 2011, 76, 9525; (c) Wasa, M.; Chan, K. S. L.; Yu, J.-Q. Chem. Lett. 2011, 40, 1004.
- 11. (a) Ge, H.; Niphakis, M. J.; Georg, G. I. J. Am. Chem. Soc. 2008, 130, 3708; (b) Zhao, J.; Zhang, Y.; Cheng, K. J. Org. Chem. **2008**, 73, 7428; (c) Wang, D.-H.; Mei, T.-S.; Yu, J.-Q. J. Am. Chem. Soc. 2008, 130, 17676; (d) Chu, J.-H.; Tsa, S.-L.; Wu, M.-J. Synthesis 2009, 22, 3757; (e) Chu, J.-H.; Lin, P.-S.; Wu, M.-J. Organometallics 2010, 29, 4058; (f) Chu, J.-H.; Lin, P.-S.; Lee, Y.-M.; Shen, W.-T.; Wu, M.-J. Chem.—Eur. J. 2011, 17, 13613; (g) Zhang, X.; Yu, M.; Yao, J.; Zhang, Y. Synlett **2012**, 463; (h) Zhao, B. Org. Biomol. Chem. 2012, 10, 7108; (i) Yao, J.; Yu, M.; Zhang, Y. Adv. Synth. Catal. 2012, 354 3205
- 12. For examples of Pd-catalyzed C-H arylation with arylboron reagents at mild temperatures (<50 °C) see: (a) Kirchberg, S.; Vogler, T.; Studer, A. Synlett 2008, 2841; (b) Nishikata, T.; Abela, A. R.; Huang, S.; Lipshutz, B. H. J. Am. Chem. Soc. 2010, 132, 4978; (c) Tredwell, M. J.; Gulias, M.; Bremeyer, N. G.; Johansson, C. C. C.; Collins, B. S. L.; Gaunt, M. J. Angew. Chem., Int. Ed. 2011, 50, 1076; (d) Wasa, M.; Collins, B. S. L., Gaunt, W. J. Angew. Chem., Int. Ed. 2011, 55, 1575, (a) 1-asa,
 Engle, K. M.; Lin, D. W.; Yoo, E. J.; Yu, J.-Q. J. Am. Chem. Soc. 2011, 133, 19598.
 Hull, K. L.; Sanford, M. S. J. Am. Chem. Soc. 2007, 129, 11904.
- 13
- Neufeldt, S. R.; Seigerman, C. K.; Sanford, M. S. Org. Lett. 2013, (Online early 14 access), in press.
- Melikyan, G. G. Synthesis 1993, 833. 15
- Reddy, B. V. S.; Reddy, L. R.; Corey, E. J. Org. Lett. 2006, 8, 3391. 16
- 17. (a) Whitfield, S. R.; Sanford, M. S. J. Am. Chem. Soc. 2007, 129, 15142; (b) Racowski, J. M.; Dick, A. R.; Sanford, M. S. J. Am. Chem. Soc. 2009, 131, 10974; (c) Racowski, J. M.; Ball, N. D.; Sanford, M. S. J. Am. Chem. Soc. 2011, 133, 18022; (d) Racowski, J. M.; Sanford, M. S. Angew. Chem., Int. Ed. 2012, 51, 3414; (e) Hickman, A. J.; Sanford, M. S. Nature 2012, 484, 177.
- Kalyani, D.; Dick, A. R.; Anani, W. Q.; Sanford, M. S. Tetrahedron 2006, 62, 11483. 18
- 19. Hull, K. L.; Anani, W. Q.; Sanford, M. S. J. Am. Chem. Soc. 2006, 128, 7134.
- 20. Desai, L. V.; Malik, H. A.; Sanford, M. S. Org. Lett. 2006, 8, 1141.
- 21. Deprez, N. R.; Sanford, M. S. J. Am. Chem. Soc. 2009, 131, 11234.
- 22. DuPriest, M. T.; Schmidt, C. L.; Kuzmich, D.; Williams, S. B. J. Org. Chem. 1986, 51, 2021
- 23 Yu, M.; Fang, H.; Yue, Y.; Chen, Y.; Chen, S. Synth. Commun. 2010, 40, 58.
- Ewing, W. R.; Mapelli, C.; Sulsky, R. B.; Haque, T. S.; Lee, V. G.; Riexinger, D. J.; 24 Martinez, R. L.; Zhu, Y. Human Glucagon-like-peptide-1 Modulators and their use in the Treatment of Diabetes and Related Conditions. PCT Int. Appl. WO 2006014287 A1, 2006.
- 25. Lohse, O.; Thevenin, P.; Waldvogel, E. Synlett 2009, 45.
- 26 Vedejs, E.; Chapman, R. W.; Fields, S. C.; Lin, S.; Schrimpf, M. R. J. Org. Chem. 1995, 60, 3020.